Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela R Wateska

Showing results (11-20 of 48) with videos related to

Pageof 5
Sort By:
Vaccine|March 9, 2019
Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general populationAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Vaccine|November 6, 2022
Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults < 65-years-oldAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
American Journal of Preventive Medicine|November 30, 2024
Cost-Effectiveness and Public Health Impact of 24-Valent Pneumococcal Conjugate Vaccine Compared With the Recommended Pneumococcal Vaccines in Older AdultsKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Journal of the American Geriatrics Society|February 23, 2020
Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older PopulationsAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
American Journal of Preventive Medicine|February 1, 2020
Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. PopulationsAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Vaccine|June 25, 2021
Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysisKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Journal of Community Health|August 12, 2019
Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged < 65 YearsAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Human Vaccines & Immunotherapeutics|January 12, 2019
An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysisAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Innovation in Aging|December 21, 2018
Potential Cost-Effectiveness of a Universal Influenza Vaccine in Older AdultsGlenson France, Angela R Wateska, Mary Patricia Nowalk, et al.
Vaccine|May 28, 2021
Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? Α value of information analysisAngela R Wateska, Mary Patricia Nowalk, Hawre Jalal, et al.
Pageof 5

Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Vaccine|March 9, 2019
Cost-effectiveness of adult pneumococcal vaccination policies in underserved minorities aged 50-64 years compared to the US general populationAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Vaccine|November 6, 2022
Cost-effectiveness of revised US pneumococcal vaccination recommendations in underserved minority adults < 65-years-oldAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
American Journal of Preventive Medicine|November 30, 2024
Cost-Effectiveness and Public Health Impact of 24-Valent Pneumococcal Conjugate Vaccine Compared With the Recommended Pneumococcal Vaccines in Older AdultsKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Journal of the American Geriatrics Society|February 23, 2020
Cost-Effectiveness of Pneumococcal Vaccination Policies and Uptake Programs in US Older PopulationsAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
American Journal of Preventive Medicine|February 1, 2020
Pneumococcal Vaccination in Adults Aged ≥65 Years: Cost-Effectiveness and Health Impact in U.S. PopulationsAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Vaccine|June 25, 2021
Should older adult pneumococcal vaccination recommendations change due to decreased vaccination in children during the pandemic? A cost-effectiveness analysisKenneth J Smith, Angela R Wateska, Mary Patricia Nowalk, et al.
Journal of Community Health|August 12, 2019
Cost-Effectiveness of Pneumococcal Vaccination and Uptake Improvement Programs in Underserved and General Population Adults Aged < 65 YearsAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Human Vaccines & Immunotherapeutics|January 12, 2019
An intervention to improve pneumococcal vaccination uptake in high risk 50-64 year olds vs. expanded age-based recommendations: an exploratory cost-effectiveness analysisAngela R Wateska, Mary Patricia Nowalk, Chyongchiou J Lin, et al.
Innovation in Aging|December 21, 2018
Potential Cost-Effectiveness of a Universal Influenza Vaccine in Older AdultsGlenson France, Angela R Wateska, Mary Patricia Nowalk, et al.
Vaccine|May 28, 2021
Is further research on adult pneumococcal vaccine uptake improvement programs worthwhile? Α value of information analysisAngela R Wateska, Mary Patricia Nowalk, Hawre Jalal, et al.
Pageof 5